EO Care Releases Latest Cannabinoid-Based Symptom Management Efficacy Data
Meaningful improvements were reported by patients after one (1) week and sustained through four (4) weeks of guided cannabinoid care, particularly among people over 50 and cancer patients. Patients also reported low rates of use-limiting side effects with further reductions after receiving updated recommended product and/or dosing guidance via EO Care’s digital care platform.
















